Zobrazeno 1 - 10
of 679
pro vyhledávání: '"Eribulin Mesylate"'
Publikováno v:
Cancer Medicine, Vol 13, Iss 10, Pp n/a-n/a (2024)
Abstract Background This prospective real‐world study aimed to assess the efficacy and safety of eribulin in the clinical practice against advanced breast cancer (ABC) in China. Patients and Methods In this study, eligible patients with inoperable
Externí odkaz:
https://doaj.org/article/8c16798eac09486db3ceeee6b5160253
Autor:
Yuxin Ma, Xinhong Shi, Kun Zhao, Shuyi Hu, Yue Shi, Yingying Jiang, Yiling Liu, Lin Lu, Yuting Chang, Fei Zhou, Yingying Dai, Zipeng Wu, Shiyi Li, Zhiying Qian, Xia Xu, Chenchen Li, Bo Shen, Guoren Zhou, Cheng Chen, Xiaohua Wang, Jifeng Feng
Publikováno v:
Frontiers in Oncology, Vol 14 (2024)
Metastatic triple-negative breast cancer (mTNBC) has the worst prognosis among breast cancer subtypes. Immune checkpoint inhibitors (ICIs) plus chemotherapy have promising survival benefits. Herein, we report a 51-year-old woman whose metastatic lesi
Externí odkaz:
https://doaj.org/article/1d41af09d69841bdb41b261312b9ab6e
Autor:
Kazumasa Oya, Yoshiyuki Nakamura, Rei Watanabe, Ryota Tanaka, Yuki Ichimura, Noriko Kubota, Yutaka Matsumura, Hideaki Tahara, Naoko Okiyama, Manabu Fujimoto, Toshifumi Nomura, Yasuhiro Fujisawa
Publikováno v:
OncoImmunology, Vol 12, Iss 1 (2023)
ABSTRACTEribulin mesylate (ERB) is a synthetic analog of halichondrin B, inhibiting tumor cell growth by disrupting microtubule function. Recently, anticancer drugs have been shown to not only act directly on tumor cells but also to exert antitumor e
Externí odkaz:
https://doaj.org/article/e8d35e9ee38e423c8bdae4bb3ecb9b00
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Takahiro Ishizaka, Keisuke Horiuchi, Shinya Kondo, Masashi Isaji, Takahiro Nakagawa, Masahiro Inoue, Hajime Rikitake, Eiko Taguchi, Michiro Susa, Masaki Yoda, Takeshi Ono, Yusuke Kozai, Kazuhiro Chiba
Publikováno v:
Bone Reports, Vol 18, Iss , Pp 101693- (2023)
Over the past few decades, the clinical outcomes of patients with cancer have significantly improved mostly owing to the development of effective chemotherapeutic treatments. However, chronic health conditions such as bone mass loss and risk of fragi
Externí odkaz:
https://doaj.org/article/8101bb42ca5d4e229cac8a44a6406be7
Publikováno v:
Breast Cancer: Targets and Therapy, Vol Volume 13, Pp 135-150 (2021)
Peng Yuan, Binghe Xu National Cancer Center, National Clinical Research Center for Cancer, Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, People’s Republic of ChinaCorrespondence: Binghe XuNa
Externí odkaz:
https://doaj.org/article/93ca463d3c6d472ea7ed8d651f94b2a4
Autor:
Wataru Goto, Shinichiro Kashiwagi, Yuka Asano, Koji Takada, Tamami Morisaki, Katsuyuki Takahashi, Hisakazu Fujita, Masatsune Shibutani, Ryosuke Amano, Tsutomu Takashima, Shuhei Tomita, Kosei Hirakawa, Masaichi Ohira
Publikováno v:
BMC Cancer, Vol 20, Iss 1, Pp 1-10 (2020)
Abstract Background Iron is required for the proliferation of cancer cells, and its depletion suppresses tumor growth. Eribulin mesylate (eribulin), a non-taxane microtubule inhibitor, disrupts the tumor microenvironment via vascular remodeling and o
Externí odkaz:
https://doaj.org/article/2a01ade984f249f59085324a59da670b
Autor:
Min Ho Park, Soo Jung Lee, Woo Chul Noh, Chang Wan Jeon, Seok Won Lee, Gil Soo Son, Byung-In Moon, Jin Sun Lee, Sung Soo Kang, Young Jin Suh, Geumhee Gwak, Tae Hyun Kim, Young Bum Yoo, Hyun-Ah Kim, Min Young Kim, Ju Yeon Kim, Joon Jeong
Publikováno v:
Breast, Vol 54, Iss , Pp 121-126 (2020)
Purpose: Approval of eribulin for metastatic breast cancer was based on data primarily from Western patients, and there is a paucity of data on the effectiveness and safety of eribulin for Asian patients. To determine the effectiveness and safety of
Externí odkaz:
https://doaj.org/article/91d7169993db48a9ba4db0f480423e62
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.